Am­i­cus CEO lob­bied FDA to re­verse FDA’s re­jec­tion of mi­gala­s­tat, claim­ing a de­lay of up to 7 years

Hand­writ­ten Note from John Crow­ley to Scott Got­tlieb.


Five days af­ter Scott Got­tlieb was sworn in as head of the FDA last May, Am­i­cus $FOLD CEO John Crow­ley was per­son­al­ly lob­by­ing him to re­verse a sting­ing re­jec­tion of mi­gala­s­tat, his new drug for rare cas­es of Fab­ry dis­ease.

CEO John Crow­ley

He overnight­ed a let­ter — ob­tained by the Pro­ject on Gov­ern­ment Over­sight — to Got­tlieb ex­plain­ing that the com­pa­ny had de­ter­mined that it would take an ex­tra­or­di­nary 5 to 7 years to com­plete a Phase III study of gas­troin­testi­nal symp­toms that the agency had de­ter­mined would be re­quired be­fore it could con­sid­er of­fer­ing a green light for mar­ket­ing. That would not be fea­si­ble in a rea­son­able amount of time, he said. And he re­viewed new da­ta that had been shared with CDER di­rec­tor Janet Wood­cock, the FDA’s Julie Beitz and oth­ers at her re­quest.

The let­ter came with a hand­writ­ten note from Crow­ley ev­i­dent­ly fol­low­ing a per­son­al con­ver­sa­tion with Got­tlieb, a high pro­file fig­ure in the biotech world.

“Con­grat­u­la­tions, again!” he wrote. “As dis­cussed, the hopes and well be­ing of so many liv­ing with rare, dev­as­tat­ing dis­eases rests now with your great lead­er­ship and wis­dom. Thanks for your at­ten­tion to the at­tached.”

In his for­mal let­ter, Crow­ley re­peat­ed two ques­tions that had been pitched to Wood­cock. Did the agency agree a new Phase III would not be need­ed? Would the agency re­view a new NDA?

Summed up Crow­ley: “We are com­mit­ted to move most ex­pe­di­tious­ly to sub­mit the NDA once we have clar­i­ty on the above.”

Scott Got­tlieb

The an­swer to his ques­tions from the agency was a stun­ning yes, one of three key re­ver­sals that the FDA made in the weeks and months af­ter Got­tlieb took the helm of the FDA. Like Am­i­cus, Eli Lil­ly suc­cess­ful­ly ap­pealed the un­ex­pect­ed re­jec­tion of baric­i­tinib, which is now back un­der re­view. Then a few weeks ago Ther­a­peu­tic­sMD — re­ject­ed a day ahead of Got­tlieb’s con­fir­ma­tion — was al­so hand­ed a stay of ex­e­cu­tion.

As the FDA re­versed it­self on mi­gala­s­tat Ju­ly 11, send­ing its share price soar­ing, Leerink’s Joseph Schwartz not­ed:

We al­so can­not rule out the po­lit­i­cal in­flu­ence of a new ad­min­is­tra­tion (and its in­cli­na­tion to­ward ap­prov­ing med­i­cines for dead­ly af­flic­tions) hav­ing an in­flu­ence in to­day’s an­nounce­ment.

The sud­den changes in stance at the agency raise se­ri­ous ques­tions. In ex­e­cut­ing these three re­ver­sals af­ter Got­tlieb was sworn in, has the agency low­ered the bar on its da­ta de­mands for new meds? And what role did Wood­cock — the con­tro­ver­sial cham­pi­on of eteplirsen who stared down fierce in­ter­nal op­po­si­tion to ap­prove Sarep­ta’s drug on sparse da­ta — as well as Got­tlieb play in push­ing for the agency’s chang­ing stance on these drugs?

I’ve asked the FDA for clar­i­fi­ca­tion on this be­fore, but nev­er got any for­mal re­sponse at the time. The agency, though, is al­so bound by strict rules re­strict­ing what it can say about any one com­pa­ny. Got­tlieb, how­ev­er, is not re­strict­ed from dis­cussing the agency’s chang­ing ap­proach to drug re­views in gen­er­al, as he has demon­strat­ed many times in re­cent months.

Fri­day af­ter­noon, act­ing as­sis­tant com­mis­sion­er Jen­nifer Ro­driguez con­tact­ed me to say that Got­tlieb was un­aware of the let­ter. Her com­ment:

Dr. Got­tlieb was not in­volved in this mat­ter and fur­ther, he was not aware of this let­ter. Prod­uct-spe­cif­ic cor­re­spon­dence that is sent to Dr. Got­tlieb by ex­ter­nal par­ties is re­ferred to the rel­e­vant cen­ters as a mat­ter of rou­tine pro­ce­dure. Fur­ther, de­ci­sions on whether to ac­cept to file an ap­pli­ca­tion or grant a drug ap­pli­ca­tion pri­or­i­ty re­view (or any of the oth­er path­ways for drug re­view) is based on spe­cif­ic cri­te­ria ap­plied to the prod­uct’s da­ta and de­ter­mined by ap­pro­pri­ate FDA ca­reer staff. To con­firm, Dr. Got­tlieb was not in­volved in de­ci­sions re­lat­ed to this prod­uct re­view.

I fol­lowed up to ask if Wood­cock, a pow­er­ful FDA of­fi­cial who Crow­ley says he had met with, felt Crow­ley’s pitch about an in­fea­si­ble de­lay of 5 to 7 years was con­sid­ered a cred­i­ble rea­son for a re­ver­sal, and if so, why. All my orig­i­nal ques­tions stand unan­swered.

Ro­driguez’s fol­lowup:

Dr. Got­tlieb was not in­volved in this mat­ter and was not in­volved in dis­cus­sions about this prod­uct-spe­cif­ic de­ci­sion.

With re­spect to your oth­er ques­tions, the FDA gen­er­al­ly can­not dis­cuss the sta­tus of a pend­ing ap­pli­ca­tion. The FDA is able to pro­vide in­for­ma­tion on ap­proved drug prod­uct ap­pli­ca­tions. In­for­ma­tion on an ap­pli­ca­tion that has yet to re­ceive an ap­proval or was de­nied ap­proval gen­er­al­ly is not re­leasable.

I didn’t hear back on whether Got­tlieb knew what Crow­ley may have re­ferred to in say­ing “as dis­cussed” in his warm per­son­al note.

In mak­ing a point, Crow­ley’s as­ser­tion that it would take up to 7 years to com­plete the re­quired Phase III al­so begs ques­tion­ing. That process was wide­ly ex­pect­ed to take about 3 years, fair­ly stan­dard for this kind of a move.

In the com­pa­ny’s de­tailed re­sponse to the re­jec­tion, Am­i­cus said it would have the da­ta in 2019.

Am­i­cus is work­ing with FDA to fi­nal­ize the clin­i­cal pro­to­col and plans to ini­ti­ate en­roll­ment in 2017, with da­ta ex­pect­ed in 2019

Did Crow­ley push that num­ber up to see if it would help per­suade reg­u­la­tors — par­tic­u­lar­ly Got­tlieb or Wood­cock — to change their minds? And wouldn’t he have to tell in­vestors, if that was the case?

We pitched those ques­tions to Crow­ley through his me­dia con­tact, and he didn’t pro­vide a di­rect re­sponse. In­stead, we got this:

Our en­gage­ment with the FDA, as with oth­er reg­u­la­to­ry bod­ies around the world, has been fo­cused on the sci­ence and da­ta we have ad­vanced through a decade of clin­i­cal re­search in Fab­ry dis­ease, as well as our un­der­stand­ing of the sig­nif­i­cant pa­tient needs we have learned from the Fab­ry com­mu­ni­ty. Our NDA sub­mis­sion in­cludes a ro­bust da­ta pack­age in­clud­ing the two largest Fab­ry piv­otal stud­ies ever con­duct­ed – which sup­port­ed ap­provals in the EU, Switzer­land, Is­rael, Cana­da and Aus­tralia.

Over a se­ries of dis­cus­sions with the FDA through­out the first half of this year, we had the op­por­tu­ni­ty to share: 1) new da­ta; 2) new analy­ses of ex­ist­ing da­ta; 3) longer-term da­ta from our ex­ten­sion stud­ies; 4) the ex­pe­ri­ence of pa­tients on com­mer­cial Galafold in Eu­rope (es­pe­cial­ly those tran­si­tion­ing from ERTs); and, 5) as re­quest­ed by FDA, pa­tient per­spec­tives on the un­met need in Fab­ry dis­ease and the lack of treat­ment op­tions in the U.S.  All of this cul­mi­nat­ed in the con­fir­ma­tion from FDA that we could sub­mit the NDA, which we did on De­cem­ber 13.

As CEO of Am­i­cus, I am ded­i­cat­ed to ad­vo­cat­ing in the best in­ter­est of pa­tients.  We stand firm­ly be­hind our en­gage­ment with FDA, and re­main com­mit­ted to ad­vanc­ing mi­gala­s­tat through the reg­u­la­to­ry process as quick­ly as pos­si­ble.

In the mean­time, Am­i­cus pushed through its new NDA for mi­gala­s­tat yes­ter­day.

Brent Saunders [Getty Photos]

UP­DAT­ED: Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

Re­gen­eron and their part­ners at Sanofi have beat the No­var­tis/Roche team to the punch on an­oth­er key in­di­ca­tion for their block­buster an­ti-in­flam­ma­to­ry drug Dupix­ent. The drug team scored an ac­cel­er­at­ed FDA ap­proval for chron­ic rhi­nos­i­nusi­tis with nasal polyps, mak­ing this the first such NDA for the field.

An­a­lysts have been watch­ing this race for awhile now, as Sanofi/Re­gen­eron won a snap pri­or­i­ty re­view for what is now their third dis­ease in­di­ca­tion for this treat­ment. And they’re not near­ly done, build­ing up hopes for a ma­jor fran­chise.

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

Back in 2014, Stephanie Tagliatela opted to take an early exit out of her PhD program after working in Mark Bear’s lab at MIT, where she specialized in the synaptic connections between neuronal cells in the brain. She never finished that PhD, but she and fellow MIT student Kartik Ramamoorthi — who was on the founding team at Voyager — came away with some ideas for a gene therapy startup.

Today, fully 5 years later, she and Ramamoorthi are taking the wraps off of a $104 million mega-round designed to take the cumulative work of their preclinical formative stage for Encoded Therapeutics into human studies. They’ve now raised $158 million since starting out in Illumina’s incubator in the Bay Area, and they believe they are firmly on track to do something unique in gene therapy.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

Two biotech uni­corns swell pro­posed IPOs, eye­ing a $600M-plus wind­fall

We’ve been wait­ing for the ar­rival of Bridge­Bio’s IPO to top off the wave of new biotech of­fer­ings sweep­ing through Nas­daq at the end of H1. And now we learn that it’s been sub­stan­tial­ly up­sized.

Ini­tial­ly pen­ciled in at a uni­corn-sized $225 mil­lion, the KKR-backed biotech has spiked that to the neigh­bor­hood of $300 mil­lion, look­ing to sell 20 mil­lion shares at $14 to $16 each. That’s an added 5 mil­lion shares, re­ports Re­nais­sance Cap­i­tal, which fig­ures the pro­posed mar­ket val­u­a­tion for Neil Ku­mar’s com­pa­ny at $1.8 bil­lion.

No­var­tis holds back the copy­cat brigade's at­tack on its top drug fran­chise — for now

A fed­er­al judge has put a gener­ic chal­lenge to No­var­tis’ block­buster mul­ti­ple scle­ro­sis drug Gilenya on hold while a patent fight plays out in court.

Judge Leonard P. Stark is­sued a tem­po­rary in­junc­tion ear­li­er this week, forc­ing My­lan, Dr. Red­dy’s Lab­o­ra­to­ries and Au­robindo Phar­ma to shelve their launch plans to al­low the patent fight to pro­ceed. He ruled that al­low­ing the gener­ics in­to the mar­ket now would per­ma­nent­ly slash the price for No­var­tis, even if it pre­vails. 

Richard Gonzalez testifying in front of Senate Finance Committee, February 2019 [AP Images]

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

Big time M&A is back. But for how long?

Over the past 18 months we’ve now seen three major buyouts announced: Takeda/Shire; Bristol-Myers/Celgene and now AbbVie/Allergan. And with this latest deal it’s increasingly clear that the sharp fall from grace suffered by high-profile players which have seen their share prices blasted has created an opening for the growth players in big pharma to up their game — in sharp contrast to the popular bolt-on deals that have been driving the growth strategy at Novartis, Merck, Roche and others.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

Af­ter get­ting beat up on all sides from mar­ket ob­servers who don’t much care for the lat­est mega-deal to ar­rive in bio­phar­ma, at least one promi­nent an­a­lyst now is start­ing to like what he sees in the num­bers for Ab­b­Vie/Al­ler­gan.

But it’s go­ing to take some en­cour­age­ment if Ab­b­Vie ex­ecs want it to last.

Ab­b­Vie’s mar­ket cap de­clined $20 bil­lion on Tues­day as the stock took a 17% hit dur­ing the day. And SVB Leerink’s Ge­of­frey Porges can see a dis­tinct out­line of an up­side af­ter re­view­ing the fun­da­men­tals of the deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

While Ako­rn works to re­vive its for­tunes, the FDA hits it with an­oth­er warn­ing let­ter

Ako­rn just can’t dig it­self out of its hole.

The spe­cial­ty gener­ic drug­mak­er has re­ceived yet an­oth­er warn­ing let­ter from the FDA this year. With­out dis­clos­ing any specifics, the Lake For­est, Illi­nois-based drug­mak­er on Wednes­day said the US reg­u­la­tor had is­sued the let­ter, cit­ing an in­spec­tion of its Som­er­set, New Jer­sey man­u­fac­tur­ing fa­cil­i­ty in Ju­ly and Au­gust of 2018. The com­pa­ny’s shares $AKRX dipped about 1.7% to $4.65 be­fore the bell.